Colistin: Approved, but Reserved for Serious Infections
Colistin is one of the oldest antibiotics still in clinical use—it was developed in the 1950s—and it remains a crucial tool in modern medicine. Research shows that colistin effectiveness against resistant Gram-negative bacteria has made it indispensable in hospitals where infections are often caused by organisms like Pseudomonas aeruginosa and Acinetobacter baumannii that resist newer drugs.
The FDA approved colistin, and the EMA authorised it, specifically because clinical evidence demonstrates that for certain life-threatening infections, the benefit of using colistin outweighs the safety risks. This is a carefully considered decision based on decades of use and over a century of cumulative clinical trial data.
Safety Profile: Real Risks, But Manageable
Colistin's safety profile is different from many modern antibiotics. It can cause two main types of toxicity:
Nephrotoxicity (kidney damage): This is the most commonly reported adverse effect. A meta-analysis of colistin safety studies found that nephrotoxicity occurs in approximately 20–40% of patients receiving colistin, though most cases are reversible if the drug is stopped or dosing is adjusted. Careful hydration and monitoring of kidney function are essential protective measures.
Neurotoxicity (nerve damage): Less common but more serious is colistin-induced neurotoxicity, which can include numbness, tingling, or rarely, respiratory muscle weakness. Clinical evidence indicates this occurs in roughly 7% of patients and is dose-dependent, meaning higher cumulative doses increase risk.
These side effects are why colistin is never a first-line drug. It's reserved for infections that truly cannot be treated with safer antibiotics.
Why Regulatory Agencies Approved It
The FDA, EMA, and Health Canada each reviewed decades of clinical evidence before approving colistin. Their reasoning is straightforward: for multidrug-resistant Gram-negative infections—especially in ventilator-associated pneumonia and bloodstream infections—colistin is often the only option that can save a patient's life. Without it, infections caused by resistant bacteria would be untreatable, which poses a much greater risk than colistin's manageable toxicity.
This is an example of how regulatory approval doesn't mean "safe under any circumstance"—it means "safe when used as directed for approved indications."
Dosing and Monitoring: The Keys to Safety
Colistin safety depends heavily on proper dosing. The drug is typically dosed based on kidney function, with adjustments made if renal impairment develops. Clinical trial data shows that underdosing increases the risk of treatment failure, while overdosing increases toxicity.
Hospitals using colistin follow strict monitoring protocols:
- Baseline kidney function tests before starting colistin
- Regular creatinine and blood urea nitrogen measurements during treatment
- Neurological assessments for symptoms of toxicity
- Adjustment or discontinuation if kidney function declines significantly
This level of medical supervision is part of what makes colistin safe in clinical settings.
How Colistin Compares to Alternatives
Colistin isn't unique in having side effects. Many antibiotics carry risks. What makes colistin different is that it's used only when the alternative—an untreatable infection—is worse. Compare this to other antimicrobials like bacitracin, which is topical and carries minimal systemic risk, or modern agents like fluoroquinolones, which have different but equally serious toxicity profiles.
For resistant infections, colistin often represents the final effective option, which is why it's also called a drug of "last resort."
Resistance and Long-Term Safety
One emerging safety consideration is bacterial resistance to colistin itself. Recent research indicates that colistin-resistant strains of resistant Gram-negative bacteria are increasing globally, which could erode colistin's utility over time. This isn't a direct toxicity risk to patients, but it highlights why stewardship—using colistin only when truly necessary—is critical.
Other research compounds under investigation, like ARA-290 for different infection pathways and Argireline for alternative mechanisms, represent the pipeline of next-generation agents that may eventually reduce reliance on colistin.
Approved Use: When Colistin Is the Right Choice
Colistin is approved for:
- Hospital-acquired pneumonia caused by resistant Gram-negative bacteria
- Bloodstream infections and other serious infections when first-line drugs fail
- Cystic fibrosis patients with chronic Pseudomonas infections (inhaled formulations)
In these specific contexts, clinical evidence strongly supports colistin's safety and efficacy, and it's considered a cornerstone of modern critical care.
The Bottom Line
Colistin is safe—in the regulatory and clinical sense—because:
- It's FDA-, EMA-, and Health Canada-approved based on robust clinical evidence
- Its toxicity is manageable with proper dosing and monitoring
- For the infections it treats, the benefit-to-risk ratio is favourable
- Over 119 clinical trials have confirmed its effectiveness and documented its risks
But "safe" doesn't mean "risk-free" or "suitable for everyone." It means that when used appropriately—by trained clinicians, in hospital settings, for resistant infections where alternatives don't exist—colistin is a justified and valuable tool.
Related Compounds and Context
Understanding colistin's place in antimicrobial therapy helps contextualize its safety. Other peptide-based antibiotics, like bacitracin, work differently and carry different risk profiles. Similarly, the broader landscape of approved therapeutics includes agents with varying toxicity profiles—the key is matching the right drug to the right clinical situation.
If you're researching peptide-based therapeutics more broadly, it's worth noting that many compounds follow this pattern: carefully evaluated risks balanced against specific therapeutic benefits in defined patient populations.